AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32102680 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and magnesium co-supplementation
Number of subjects: 108
Study 32102680 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 108
Study 32102680 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 108
Study 32102680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 33054533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast
Number of subjects: 244
Study 32986960 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD-Relative Intensity (COPD-RI) exercise training
Number of subjects: 21
Study 32986960 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD-Absolute Intensity (COPD-AI) exercise training
Number of subjects: 21
Study 32986960 — intervention group
Group type: COMPARATOR
Intervention: Sedentary Healthy Subjects (SHS) exercise training
Number of subjects: 21
Study 32986960 — intervention group
Group type: COMPARATOR
Intervention: COPD serum
Number of subjects: 21
Study 32986960 — intervention group
Group type: COMPARATOR
Intervention: SHS serum
Number of subjects: 21
Study 35599474 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-BFR (low-intensity with blood flow restriction, 30% of 1RM)
Number of subjects: 32
Study 35599474 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-HI (high-intensity without blood flow restriction, 70% of 1RM)
Number of subjects: 32
Study 35599474 — intervention group
Group type: COMPARATOR
Intervention: RT-CON (low-intensity without blood flow restriction, 30% of 1RM)
Number of subjects: 32
Study 34763338 — intervention group
Group type: COMPARATOR
Intervention: 3% Hypertonic Saline (HS), 5 ml/kg as continuous infusion, titrated every 6 hours to achieve serum sodium <160
Number of subjects: 51
Study 34763338 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% Mannitol (MT), 1 g/kg as IV bolus, repeated every six hours
Number of subjects: 51
Study 32277519 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized training of emotion recognition ability (TERA)
Number of subjects: 40
Study 32277519 — intervention group
Group type: COMPARATOR
Intervention: Sham training (recognition of different types of clouds)
Number of subjects: 40
Study 35078404 — intervention group
Group type: EXPERIMENTAL
Intervention: 1L polyethylene glycol (PEG) NER1006 (N2D)
Number of subjects: 1307
Study 35078404 — intervention group
Group type: EXPERIMENTAL
Intervention: 1L polyethylene glycol (PEG) NER1006 (N1D)
Number of subjects: 1307
Study 35078404 — intervention group
Group type: EXPERIMENTAL
Intervention: 1L polyethylene glycol (PEG) NER1006 (N2D or N1D)
Number of subjects: 1307
Study 35078404 — intervention group
Group type: EXPERIMENTAL
Intervention: 1L polyethylene glycol (PEG) NER1006
Number of subjects: 1307
Study 35078404 — intervention group
Group type: COMPARATOR
Intervention: Time between preparation and colonoscopy
Number of subjects: 1307
Study 32421187 — intervention group
Group type: EXPERIMENTAL
Intervention: BariFit mHealth intervention (16-week pilot)
Number of subjects: 51
Study 32421187 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable step goals
Number of subjects: 51
Study 32421187 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity suggestions (SMS-delivered)
Number of subjects: 51
Study 35555290 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min WBHS
Number of subjects: 20
Study 35555290 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-min WBHS
Number of subjects: 20
Study 32844328 — intervention group
Group type: EXPERIMENTAL
Intervention: Dating Matters (DM)
Number of subjects: 1662
Study 32844328 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-Care (SC)
Number of subjects: 1662
Study 33998168 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose photodynamic therapy (PDT)
Number of subjects: 39
Study 33998168 — intervention group
Group type: COMPARATOR
Intervention: High-density subthreshold micropulse laser (HSML) treatment
Number of subjects: 39
Study 33752634 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazardous alcohol use (AUDIT ≥8)
Number of subjects: 166
Study 32141320 — intervention group
Group type: EXPERIMENTAL
Intervention: Early weightbearing at 2 weeks postoperation
Number of subjects: 50
Study 32141320 — intervention group
Group type: COMPARATOR
Intervention: Late weightbearing at 6 weeks postoperation
Number of subjects: 50
Study 36377063 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) program for 14 ± 2 weeks
Number of subjects: 90
Study 36377063 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 90
Study 36377063 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) program
Number of subjects: 90
Study 32210537 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX group (loading dose of DEX at 0.5 μg/kg within 10 min, followed by infusion of DEX at 0.5 μg/kg/h until the end of surgery and PCIA for 2 days with DEX plus sufentanil)
Number of subjects: 160
Study 32210537 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX group
Number of subjects: 160
Study 32210537 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 160
Study 33323237 — intervention group
Group type: EXPERIMENTAL
Intervention: DBLG1 hybrid closed-loop system
Number of subjects: 68
Study 33323237 — intervention group
Group type: COMPARATOR
Intervention: Sensor-assisted pump therapy
Number of subjects: 68
Study 35939964 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF) on alcohol use
Number of subjects: 499
Study 35939964 — intervention group
Group type: COMPARATOR
Intervention: Control topics within a broader digital competition
Number of subjects: 499
Study 33323253 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative intelligent insole system with audiovisual alerts via smartwatch
Number of subjects: 90
Study 33323253 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alerts)
Number of subjects: 90
Study 33323253 — intervention group
Group type: EXPERIMENTAL
Intervention: Good compliers in intervention group (n=40)
Number of subjects: 90
Study 33323253 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-ulcerating patients
Number of subjects: 90
Study 35702841 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 480
Study 35702841 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 480
Study 35702841 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 480
Study 35702841 — intervention group
Group type: EXPERIMENTAL
Intervention: Remogliflozin
Number of subjects: 480
Study 33653300 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus medication self-management intervention
Number of subjects: 136
Study 33653300 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 136
Study 35258131 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous tooth roots (TRs)
Number of subjects: 28
Study 35258131 — intervention group
Group type: COMPARATOR
Intervention: Cortical autogenous bone blocks (ABs)
Number of subjects: 28
Study 35258131 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TR and AB)
Number of subjects: 28
Study 32061431 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillomandibular fixation (MMF)
Number of subjects: 40
Study 32061431 — intervention group
Group type: COMPARATOR
Intervention: Rigid internal fixation (ORIF)
Number of subjects: 40
Study 33119861 — intervention group
Group type: EXPERIMENTAL
Intervention: SDZ-ADL 40 mg subcutaneous every other week from Week 0 to Week 24, continued for patients with moderate response at Week 24 (n = 159)
Number of subjects: 353
Study 33119861 — intervention group
Group type: COMPARATOR
Intervention: ref-ADL (n = 176) switched to SDZ-ADL at Week 24 (n = 166)
Number of subjects: 353
Study 33119861 — intervention group
Group type: EXPERIMENTAL
Intervention: SDZ-ADL after switching from ref-ADL
Number of subjects: 353
Study 33119861 — intervention group
Group type: COMPARATOR
Intervention: ref-ADL switched to SDZ-ADL
Number of subjects: 353
Study 33119861 — intervention group
Group type: EXPERIMENTAL
Intervention: SDZ-ADL
Number of subjects: 353
Study 36286853 — intervention group
Group type: EXPERIMENTAL
Intervention: LPD with soy protein (60% soy protein + 40% vegetable proteins) + KA
Number of subjects: 85
Study 36286853 — intervention group
Group type: COMPARATOR
Intervention: LPD (60% animal protein + 40% vegetable protein) + KA
Number of subjects: 85
Study 33523513 — intervention group
Group type: EXPERIMENTAL
Intervention: tildrakizumab 100 mg
Number of subjects: 120
Study 33523513 — intervention group
Group type: EXPERIMENTAL
Intervention: tildrakizumab 200 mg
Number of subjects: 120
Study 35691324 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 (AZD1222) vaccine, 5 × 10^10 viral particles, two doses, administered 28 days or 84 days apart.
Number of subjects: 262
Study 35691324 — intervention group
Group type: COMPARATOR
Intervention: Control group (capsular group B meningococcal vaccine).
Number of subjects: 262
Study 34561265 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (three supervised, high-intensity interval training sessions per week for 12 weeks)
Number of subjects: 66
Study 34561265 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 66
Study 36261342 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar attachment retention
Number of subjects: 50
Study 36261342 — intervention group
Group type: COMPARATOR
Intervention: Solitary attachment retention
Number of subjects: 50
Study 33858985 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge translation intervention (telephone surveys, 1-year audit with feedback, guidelines package, academic detailing visit)
Number of subjects: 3424
Study 33858985 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 3424
Study 33858985 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge translation intervention
Number of subjects: 3424
Study 33858985 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3424
Study 34362359 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician
Number of subjects: 452
Study 34362359 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician using AI
Number of subjects: 452
Study 34362359 — intervention group
Group type: COMPARATOR
Intervention: Automated AI
Number of subjects: 452
Study 34362359 — intervention group
Group type: COMPARATOR
Intervention: Physician (vs. automated AI)
Number of subjects: 452
Study 34362359 — intervention group
Group type: COMPARATOR
Intervention: AI (vs. physician only)
Number of subjects: 452
Study 32682996 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Education + text-message-based Positive Affect intervention
Number of subjects: 0
Study 32682996 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Education control condition
Number of subjects: 0
Study 35987819 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral enteric coating lactoferrin (700 mg/day for at least 28 consecutive days)
Number of subjects: 117
Study 35987819 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved microbiota after lactoferrin supplementation
Number of subjects: 117
Study 35987819 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-RIF)
Number of subjects: 117
Study 35987819 — intervention group
Group type: COMPARATOR
Intervention: Control group (RIF)
Number of subjects: 117
Study 33949022 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery Start Time (SST) - Afternoon implant placement
Number of subjects: 201
Study 33949022 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-placement ridge augmentation
Number of subjects: 201
Study 33949022 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative complications
Number of subjects: 201
Study 33949022 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous soft tissue grafting
Number of subjects: 201
Study 33949022 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous bone grafting
Number of subjects: 201
Study 33949022 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement with sedation
Number of subjects: 201
Study 32268191 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast disintegrating and dissolving Aspirin® tablet (FDDT)
Number of subjects: 30
Study 32268191 — intervention group
Group type: COMPARATOR
Intervention: Regular Aspirin® tablet (RT)
Number of subjects: 30
Study 32268191 — intervention group
Group type: EXPERIMENTAL
Intervention: FDDT with food
Number of subjects: 30
Study 32268191 — intervention group
Group type: COMPARATOR
Intervention: RT under fed conditions
Number of subjects: 30
Study 35718771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment (SBP 110–120 mmHg) in SPRINT
Number of subjects: 0
Study 35718771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment (SBP 120–130 mmHg) in SPRINT
Number of subjects: 0
Study 35718771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment (SBP 110–120 mmHg) in ACCORD-BP
Number of subjects: 0
Study 35718771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment (SBP 120–130 mmHg) in ACCORD-BP
Number of subjects: 0
Study 35718771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment
Number of subjects: 0
Study 35718771 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved very low BP levels
Number of subjects: 0
Study 32252803 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise augmented cognitive behaviour therapy
Number of subjects: 0
Study 32252803 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33577989 — intervention group
Group type: EXPERIMENTAL
Intervention: Email
Number of subjects: 57
Study 33577989 — intervention group
Group type: COMPARATOR
Intervention: Attachment
Number of subjects: 57
Study 32047155 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted supermicrosurgical lymphatico-venous anastomosis (LVA)
Number of subjects: 0
Study 32047155 — intervention group
Group type: COMPARATOR
Intervention: Manual supermicrosurgical lymphatico-venous anastomosis (LVA)
Number of subjects: 0
Study 36229115 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Triple P‐Positive Parenting Program plus Building Coparenting Alliance
Number of subjects: 100
Study 36229115 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 100
Study 33666594 — intervention group
Group type: COMPARATOR
Intervention: Iron Path app (IP)
Number of subjects: 27
Study 33273714 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid lateral flow immunoassay for fluorescence detection of SARS-CoV-2 RNA
Number of subjects: 670
Study 33273714 — intervention group
Group type: COMPARATOR
Intervention: Quantitative PCR with reverse transcription (ground truth)
Number of subjects: 670
Study 36175613 — intervention group
Group type: EXPERIMENTAL
Intervention: MUA plus exercise (EX)
Number of subjects: 134
Study 36175613 — intervention group
Group type: COMPARATOR
Intervention: CLX plus exercise (EX)
Number of subjects: 134
Study 34702760 — intervention group
Group type: EXPERIMENTAL
Intervention: Th2 cytokines added to an in vitro three-dimensional human skin model
Number of subjects: 0
Study 34702760 — intervention group
Group type: COMPARATOR
Intervention: Normal human skin
Number of subjects: 0
Study 34702760 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro three-dimensional skin model
Number of subjects: 0
Study 34702760 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 33561587 — intervention group
Group type: EXPERIMENTAL
Intervention: LET monitoring (LET[+])
Number of subjects: 86
Study 33561587 — intervention group
Group type: COMPARATOR
Intervention: No LET monitoring (LET[−])
Number of subjects: 86
Study 33170262 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel cancer therapies
Number of subjects: 191
Study 33098442 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic aqueductoplasty (EA)
Number of subjects: 20
Study 32309918 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise training for four weeks
Number of subjects: 0
Study 32309918 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive exercise for eight months
Number of subjects: 0
Study 32309918 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive exercise for eight months (previously published data)
Number of subjects: 0
Study 33434615 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications for Alcohol Use Disorder (AUD)
Number of subjects: 0
Study 32591820 — intervention group
Group type: EXPERIMENTAL
Intervention: (lipo)glycopeptides (LGP/GPs) alone
Number of subjects: 20
Study 32591820 — intervention group
Group type: EXPERIMENTAL
Intervention: (lipo)glycopeptides (LGP/GPs) in combination with β-lactams
Number of subjects: 20
Study 32591820 — intervention group
Group type: EXPERIMENTAL
Intervention: LGPs (dalbavancin, oritavancin, telavancin)
Number of subjects: 20
Study 32591820 — intervention group
Group type: EXPERIMENTAL
Intervention: combinations of LGP/GPs and β-lactams
Number of subjects: 20
Study 36382660 — intervention group
Group type: EXPERIMENTAL
Intervention: Written counseling
Number of subjects: 145
Study 36382660 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral counseling
Number of subjects: 145
Study 36382660 — intervention group
Group type: EXPERIMENTAL
Intervention: Written + photograph counseling
Number of subjects: 145
Study 36382660 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral + photograph counseling
Number of subjects: 145
Study 36382660 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention overall
Number of subjects: 145
Study 34715821 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal rivastigmine for 12 months
Number of subjects: 600
Study 34715821 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo for 12 months
Number of subjects: 600
Study 34715821 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal rivastigmine
Number of subjects: 600
Study 34715821 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 600
Study 33256382 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperimmune plasma (250-300 ml units with neutralizing antibodies titer ≥1:160)
Number of subjects: 46
Study 33256382 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperimmune plasma
Number of subjects: 46
Study 35196863 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 24893
Study 35196863 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (placebo)
Number of subjects: 24893
Study 34371000 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwater endoscopic mucosal resection (UEMR)
Number of subjects: 0
Study 34371000 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopic mucosal resection (CEMR)
Number of subjects: 0
Study 34371000 — intervention group
Group type: EXPERIMENTAL
Intervention: Both UEMR and CEMR
Number of subjects: 0
Study 34951060 — intervention group
Group type: EXPERIMENTAL
Intervention: App use group
Number of subjects: 73
Study 34951060 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-app use group
Number of subjects: 73
Study 34951060 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 34959789 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g/day of Neptune krill oilTM (550 mg EPA/DHA and 150 mg choline)
Number of subjects: 35
Study 34959789 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 35
Study 34091453 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormethine gel
Number of subjects: 0
Study 34091453 — intervention group
Group type: COMPARATOR
Intervention: Chlormethine ointment
Number of subjects: 0
Study 34091453 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact dermatitis
Number of subjects: 0
Study 36055074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 43
Study 36055074 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 43
Study 36055074 — intervention group
Group type: COMPARATOR
Intervention: Fusion surgery in Supine position
Number of subjects: 43
Study 36055074 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion surgery in Lateral position
Number of subjects: 43
Study 32872310 — intervention group
Group type: EXPERIMENTAL
Intervention: In-ear SpO2 measurement
Number of subjects: 0
Study 32872310 — intervention group
Group type: COMPARATOR
Intervention: Right index finger measurement (control)
Number of subjects: 0
Study 35467935 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 4744
Study 35467935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4744
Study 34553690 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-source feedback (MSF)
Number of subjects: 32
Study 34553690 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-source feedback (MSF) after crossover
Number of subjects: 32
Study 34553690 — intervention group
Group type: COMPARATOR
Intervention: Traditional feedback after crossover
Number of subjects: 32
Study 36166424 — intervention group
Group type: COMPARATOR
Intervention: Non-HD days
Number of subjects: 517
Study 36166424 — intervention group
Group type: EXPERIMENTAL
Intervention: HD days
Number of subjects: 517
Study 32351173 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT‐A)
Number of subjects: 40
Study 35416910 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (15 mg once daily)
Number of subjects: 984
Study 35416910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study 34374082 — intervention group
Group type: EXPERIMENTAL
Intervention: Black patients
Number of subjects: 392
Study 34374082 — intervention group
Group type: COMPARATOR
Intervention: White patients
Number of subjects: 392
Study 34374082 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS mutant status
Number of subjects: 392
Study 34374082 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance status score of 1
Number of subjects: 392
Study 34374082 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥3 metastatic sites
Number of subjects: 392
Study 33374368 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime green walking
Number of subjects: 48
Study 33374368 — intervention group
Group type: COMPARATOR
Intervention: Daytime urban walking
Number of subjects: 48